AIM ImmunoTech Inc. has historically implemented corporate stock split actions, including reverse stock splits on public exchanges, to manage its share capitalization and maintain compliance with minimum bid price rules mandated by major stock markets. These structural adjustments are carefully documented in official corporate proxy statements and regulatory filings submitted to federal securities authorities. Investors reviewing historical performance charts, adjusted cost bases, or long-term valuation trends should consult the investor relations portal of the company for exact historical split execution dates and precise conversion ratios.